Ingenia Therapeutics Goes Public on KOSDAQ to Accelerate Pipeline of Next-Generation Vascular Antibody Therapeutics

by Business Wire • 2026/08/18 • 0 Comments

WATERTOWN, Mass.--(BUSINESS WIRE)--Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced today that its shares have begun trading on the KOSDAQ market. The IPO marks a significant milestone as the company accelerates the development and global commercialization of its proprietary vascular stabilization pipeline. Founded in Boston in 2018, Ingenia is developing next-generation antibody therapeutics based on technologies ori

← In this era of glaucoma, is there a role for topical medications?

Stuart Therapeutics, Inc. Appoints David Jakeman as Chief Financial Officer →

Post navigation